Biocytogen Pharmaceuticals (Beijing) Co., Ltd., a biotechnology company, engages in the research and development of novel antibody-based drugs and pre-clinical research services in the People's Republic of China, the United States, and internationally. It operates through five segments: Gene-editing services, Pre-clinical pharmacology and efficacy evaluation, Animal models selling, Antibody development, and Innovative drugs development. The Gene-editing services segment provides the customized gene editing services based on animals as well as cells to meet the needs of basic science research and drug development of the customers; Pre-clinical pharmacology and efficacy evaluation segment provides the pre-clinical pharmacology service for drug efficacy and toxicity evaluation; Animal models selling segment breeds and sells the animal models for the external and internal use, including set of genetically engineered mice, disease mouse models and aged small animals; Antibody development segment utilises the Group's own antibody discovery platforms to identify antibodies which have the potential to become drug candidates; and Innovative drugs development segment engaged in research and development of innovative drugs with a focus on oncology and autoimmune disease therapeutics. The company also offers YH001, a recombinant humanized anti-cytotoxic t-lymphocyte associated protein 4 immunoglobulin G1 (IgG1) monoclonal antibody for the treatment of patients with advanced solid tumors; It also develops YH002, a recombinant humanized IgG1 antibody that targets the human tumor necrosis factor receptor superfamily, member 4 receptor, which is Phase I clinical trial. The company has collaboration with Syncromune, Inc.; a license agreement with RemeGen Co., Ltd.; license agreement with Chipscreen NewWay Biosciences. Biocytogen Pharmaceuticals (Beijing) Co., Ltd. was founded in 2008 and is headquartered in Beijing, China.